Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality - PubMed

Affiliations

• PMID: 25075769
• DOI: 10.1038/ki.2014.275

Free article

Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality

George R Bailie et al. Kidney Int. 2015 Jan.

Free article

Abstract

Intravenous (IV) iron is required for optimal management of anemia in the majority of hemodialysis (HD) patients. While IV iron prescription has increased over time, the best dosing strategy is unknown and any effect of IV iron on survival is unclear. Here we used adjusted Cox regression to analyze associations between IV iron dose and clinical outcomes in 32,435 HD patients in 12 countries from 2002 to 2011 in the Dialysis Outcomes and Practice Patterns Study. The primary exposure was total prescribed IV iron dose over the first 4 months in the study, expressed as an average dose/month. Compared with 100-199 mg/month (the most common dose range), case-mix-adjusted mortality was similar for the 0, 1-99, and 200-299 mg/month categories but significantly higher for the 300-399 mg/month (HR of 1.13, 95% CI of 1.00-1.27) and 400 mg/month or more (HR of 1.18, 95% CI of 1.07-1.30) groups. Convergent validity was proved by an instrumental variable analysis, using HD facility as the instrument, and by an analysis expressing IV iron dose/kg body weight. Associations with cause-specific mortality (cardiovascular, infectious, and other) were generally similar to those for all-cause mortality. The hospitalization risk was elevated among patients receiving 300 mg/month or more compared with 100-199 mg/month (HR of 1.12, 95% CI of 1.07-1.18). In light of these associations, a well-powered clinical trial to evaluate the safety of different IV iron-dosing strategies in HD patients is urgently needed.

Comment in

• Intravenous iron administration: new observations and time for the next steps.

  Weiss G, Kronenberg F. Weiss G, et al. Kidney Int. 2015 Jan;87(1):10-2. doi: 10.1038/ki.2014.324. Kidney Int. 2015. PMID: 25549119

Similar articles

• Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F, McCullough KP, Nolen JG, Port FK, Pisoni RL. Robinson BM, et al. BMC Nephrol. 2017 Nov 9;18(1):330. doi: 10.1186/s12882-017-0745-9. BMC Nephrol. 2017. PMID: 29121874 Free PMC article.

• Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Bailie GR, et al. Nephrol Dial Transplant. 2013 Oct;28(10):2570-9. doi: 10.1093/ndt/gft062. Nephrol Dial Transplant. 2013. PMID: 24078642

• Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.

  Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB. Charytan C, et al. Nephrol Dial Transplant. 2013 Apr;28(4):953-64. doi: 10.1093/ndt/gfs528. Epub 2012 Dec 5. Nephrol Dial Transplant. 2013. PMID: 23222534 Clinical Trial.

• The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.

  Qunibi WY. Qunibi WY. Arzneimittelforschung. 2010;60(6a):399-412. doi: 10.1055/s-0031-1296304. Arzneimittelforschung. 2010. PMID: 20648931 Review.

• The safety of intravenous iron preparations: systematic review and meta-analysis.

  Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. Avni T, et al. Mayo Clin Proc. 2015 Jan;90(1):12-23. doi: 10.1016/j.mayocp.2014.10.007. Epub 2014 Oct 30. Mayo Clin Proc. 2015. PMID: 25572192 Review.

Cited by

• Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period.

  Karaboyas A, Morgenstern H, Waechter S, Fleischer NL, Vanholder R, Jacobson SH, Sood MM, Schaubel DE, Inaba M, Pisoni RL, Robinson BM. Karaboyas A, et al. Clin Kidney J. 2019 Jul 5;13(3):425-433. doi: 10.1093/ckj/sfz065. eCollection 2020 Jun. Clin Kidney J. 2019. PMID: 32699623 Free PMC article.

• Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis.

  Salim SA, Cheungpasitporn W, Elmaraezy A, Jawafi O, Rahman M, Aeddula NR, Tirupathi R, Fülöp T. Salim SA, et al. Int Urol Nephrol. 2019 Oct;51(10):1855-1865. doi: 10.1007/s11255-019-02273-4. Epub 2019 Sep 4. Int Urol Nephrol. 2019. PMID: 31485910

• Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F, McCullough KP, Nolen JG, Port FK, Pisoni RL. Robinson BM, et al. BMC Nephrol. 2017 Nov 9;18(1):330. doi: 10.1186/s12882-017-0745-9. BMC Nephrol. 2017. PMID: 29121874 Free PMC article.

• Ferric pyrophosphate: good things come to those who wait?

  Fell LH, Fliser D, Heine GH. Fell LH, et al. Nephrol Dial Transplant. 2015 Dec;30(12):1942-4. doi: 10.1093/ndt/gfv287. Epub 2015 Jul 21. Nephrol Dial Transplant. 2015. PMID: 26203048 Free PMC article.

• Iron deficiency and supplementation in heart failure.

  Lakhal-Littleton S, Cleland JGF. Lakhal-Littleton S, et al. Nat Rev Cardiol. 2024 Jul;21(7):463-486. doi: 10.1038/s41569-024-00988-1. Epub 2024 Feb 7. Nat Rev Cardiol. 2024. PMID: 38326440 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • H1 Connect

• Medical

  • MedlinePlus Health Information